Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4088044 in Healthy Participants
NCT07090785Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of LY4088044 (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events at Day 190. Started Jul 2025; status: recruiting.
02
Drugs
LY4088044
Beyond the preview
Go deeper on NCT07090785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090785.